Phase 3 Readout

LRMR: Phase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy a

Name: Phase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy a
Start: 2029-12-01
End: 2029-12-01

December 1, 2029. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: December 1, 2029
Company: Larimar Therapeutics, Inc. (LRMR)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy a

December 1, 2029

LRMR overview →

Company: Larimar Therapeutics, Inc. (LRMR)
Indication: Friedreich Ataxia; Friedreich's Ataxia